Extrapyramidal side-effects and dopamine D2/3 receptor binding in substantia nigra

Nordic Journal of Psychiatry

Volumn 64, Issue 4, 2010, Pages 233-238

  Tuppurainen, Heli ^a   Kuikka, Jyrki T ^b   Viinamki, Heimo ^b   Husso, Minna ^b   Tiihonen, Jari ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Antipsychotics; Dopamine; Extrapyramidal symptoms; Receptor binding; Substantia nigra

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; EPIDEPRIDE; EPIDEPRIDE I 123; HALOPERIDOL; IODINE 123; NEUROLEPTIC AGENT; OLANZAPINE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEBEPHRENIA; HUMAN; IMAGE ANALYSIS; MALE; MOTOR PERFORMANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANOID SCHIZOPHRENIA; RATING SCALE; SCHIZOPHRENIA; SIMPLE SCHIZOPHRENIA; SIMPSON AND ANGUS SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; TEMPORAL CORTEX; BRAIN MAPPING; DRUG EFFECTS; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; METABOLISM; PROCEDURES;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN MAPPING; CLOZAPINE; FEMALE; HALOPERIDOL; HUMANS; MAGNETIC RESONANCE IMAGING, INTERVENTIONAL; MALE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77954791777     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039480903484076     Document Type: Article

References (53)

1. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993;54:133-139
2. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998;59:69-75.
3. Wirshing WC. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 2001;62 Suppl 21:15-18
4. Casey DE. Pathopsysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004;65 Suppl 9:25-28
5. Seeman P, Tallerico T. Antipsychotic drugs elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998;3:123-134
6. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-369
7. Abi-Dargham A, Laruelle M. Mechanism of action of second generation antipsychotic drugs in schizophrenia: Insight from brain imaging studies. Eur Psychiatry 2005;20:15-27.
8. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992;49: 538-544
9. Scherer J, Tatsch K, Schwarz J, Oertel WH, Konjarczyk M, Albus M. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr Scand 1994;90:266-268
10. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A PET study. Life Sci 1995;57: PL103-7.
11. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520
12. Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, et al. Striatal vs. extrastriatal dopamine D2 receptors in antipsychotic response-A double-blind PET study in schizophrenia. Neuropsy- chopharmacology 2007;32:1209-1215
13. Schroder J, Silvestri S, Bubeck B, Karr M, Demisch S, Scherrer S, et al. D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: A follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment. Biol Psychiatry 1998;43:660-665
14. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study. Psychopharmacology 2000;152:174-180
15. Double KL, Crocker AD. Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone. Proc Natl Acad Sci USA 1995;92:1669-1673
16. Crocker AD, Hemsley KM. An animal model of extrastriatal side effects induced by antipsychotic drugs: Relationship with D2 dopamine receptor occupancy. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:573-590
17. Meador-Woodruff JH, Damask SP, Watson SJ Jr. Differential expression of autoreceptors in the ascending dopamine systems of the human brain. Proc Natl Acad Sci USA 1994;91:8297-8301
18. Hurd YL, Suzuki M, Sedvall GC. D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain. J Chem Neuroanat 2001;22:127-137.
19. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, et al. Occupancy of striatal and extrastriatal dopamine d(2)/d(3) receptors by olanzapine and haloperidol. Neuropsychopharmacology 2005;12:2283-2289
20. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006;31:1991-2001.
21. Tuppurainen H, Kuikka JT, ViinamAki H, Husso M, Tiihonen J. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine. Psychiatry Clin Neurosci 2009;63:529-537
22. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
23. Kuikka JT, Akerman KK, Hiltunen J, Bergstrom KA, Rasanen P, Vanninen E, et al. Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography. Eur J Nucl Med 1997:24, 483-487
24. Hemsley KM, Crocker AD. The effect of an irreversible dopamine receptor antagonist, Ar-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), on the regulation of muscle tone in the rat: The role of the substantia nigra. Neurosci Lett 1998;251:77-80.
25. Hemsley KM, Crocker AD. Raclopride and chlorpromazine, but not clozapine, increase muscle rigidity in the rat: Relationship with D2 dopamine receptor occupancy. Neuropsychopharmacology 1999;21:101-109
26. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983;3:1607-1619
27. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963;20:140-144
28. Pucak ML, Grace AA. Evidence that systemically administered dopamine antagonists activate dopamine neuron firing primarily by blockade of somatodendritic auroreceptors. J Pharmacol Exp Ther 1994;271:1181-1192
29. Grace AA, Bunney BS. Induction of depolarization block in midbrain dopamine neurons by repeated administration of haloperidol: Analysis using in vivo intracellular recording. J Pharmacol Exp Ther 1986;238:1092-1100
30. Grace AA. The depolarization block hypothesis of neuroleptic action: Implications for the etiology and treatment of schizophrenia. J Neural Transm Suppl 1992;36:91-131.
31. Grander G, Vernaleken I, Muller MJ, Davids E, Heydari N, Buchholz HG, et al. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 2003;28:787-794
32. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983;221:1054-1057
33. Timmerman W, Heijmen M, Westerink BHC, Bruggeman R, den Boer JA. Effects of acute and chronic administration of olanzapine in comparison to clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain. Psychopharmacology 1999;144:286-294
34. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on Extrapyramidal function. CNS Drugs 2002;16:23-45.
35. Weiden PJ. EPS profiles: The atypical antipsychotics are not the same. J Psychiatr Pract 2007;13:13-24.
36. Vernaleken I, Siessmeier T, Buchholz HG, Hartter S, Hiemke C, Stoeter P, et al. High striatal occupancy of D2-like dopamine receptors by amisulpiride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol 2004;7:421-430
37. Seeman P, Bzowej NH, Guan HC, Bergeron C, Becker LE, Reynolds GP, et al. Human brain dopamine receptors in children and aging adults. Synapse 1987;1:399-404.
38. Ichise M, Ballinger JR, Tanaka F, Moscovitch M, St. George-Hyslop PH, Raphael D, et al. Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT. J Nucl Med 1998;39:1511-1518
39. Kaasinen V, Vilkman H, Hietala J, Nagren K, Helenius H, Olsson H, et al. Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiol Aging 2000;21:683-688
40. Cabello CR, Thune JJ, Pakkenberg H, Pakkenberg B. Ageing of substantia nigra in humans: Cell loss may be compensated by hypertrophy. Neuropathol Appl Neurobiol 2002;28:283-291
41. Wong DF, Pearlson GD, Tune LE, Young LT, Melzer CC, Dannals RF, et al. Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab 1997;3:331-341
42. Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: A PET study with [11C]FLB 457. Int J Neuropsychophar- macol 2003;6:361-370
43. Volkow N, Gur RC, Wang GJ, Fowler JS, Moberg PJ, Ding YS, et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry 1998;155:344-349
44. Pinborg LH, Videbaek C, Knudsen GM, Swahn CG, Halldin C, Friberg L, et al. Dopamine D(2) quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion. Synapse 2000;36:322-329
45. Hall H, Farde L, Halldin C, Hurd YL, Pauli S, Sedvall G. Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride. Synapse 1996;23:115-123
46. Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: Comparison with D2 receptor expressing neurons. Neuropsychopharmacology 1999;20:60-80.
47. Okubo Y, Olsson H, Ito H, Lofti M, Suhara T, Halldin C, et al. PET mapping of extrastriatal D2-like dopamine receptors in the human brain using an anatomic standardization technique and [11C]FLB 457. NeuroImage 1999;10:666-674
48. Tuppurainen H, Kuikka JT, Laakso MP, Viinamaki H, Husso M, Tiihonen J. Midbrain dopamine D2/3 receptor binding in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006;256:382-387
49. Janno S, Holi MM, Tuisku K, Wahlbeck K. Validity of Simpson- Angus Scale (SAS) in a naturalistic schizophrenic population. BMC Neurology 2005;5:5.
50. Kessler RM, Ellis JR, Eden M. Analysis of emission tomographic scan data: Limitations imposed by resolution and background. J Comput Assist Tomogr 1984;8:514-522
51. Fox PT, Mintun MA, Reiman EM, Raichle ME. Enhanced detection of focal brain responses using intersubject averaging and change- distribution analysis of subtracted PET images. J Cereb Blood Flow Metab 1988;8:642-653
52. Ichise M, Fujita M, Seibyl JP, Verhoeff NP, Baldwin RM, Zoghbi SS, et al. Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT. J Nucl Med. 1999;40:1902-1912
53. Pinborg LH, Videbaek C, Ziebell M, Mackeprang T, Friberg L, Rasmussen H, et al. [123I]Epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: Implications for the use of cerebellum as a reference region. NeuroImage 2007;34:1450-1453